Scientific Committee

Stéphane Baudouin

Ph.D. – senior lecturer at Cardiff University

Dr. Baudouin's work focuses on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions, in particular ASD or schizophrenia.

Denis Jabaudon

MD, Ph.D. – Director of the Geneva University Neurocenter

Dr. Jabaudon is Director of the Geneva University Neurocenter, Clinical neurologist and Professor at the Geneva University Hospital.

He is investigating interactions between genes and environment during normal and abnormal brain development with a focus on mechanisms controlling cortical development.

Walter Kaufmann

MD, Ph.D. (President of the Scientific Committee) – clinician and researcher specializing in intellectual disability and ASD

Dr. Kaufmann was a member of the DSM-5 Autism committee. Former Professor of Neurology at Harvard Medical School and a Simons Investigator at Massachusetts Institute of Technology’s Simons Center for the Social Brain. His research uses a multidisciplinary approach to understanding the basis of cognitive and behavioral problems in children with genetic disorders associated with intellectual disability and autism spectrum disorder, with an emphasis on developing new therapeutic interventions.

Christian Lüscher

MD – neurologist and professor of neuroscience at the University of Geneva

Dr. Lüscher's work has focused on studying the hypothesis that altered synaptic transmission evoked by addictive drugs causes adaptive behaviors. Dr. Lüscher’s expertise in circuit neuroscience has extended to ASD through the study of how SHANK3 insufficiency affects specific neural circuits. Dr. Lüscher is an advanced ERC grant holder.

Luca Santarelli

MD (Advisor to the Scientific Committee) – Former Senior Vice President and Head of Neuroscience, Ophthalmology and Rare Diseases at Roche

Dr. Santarelli has more than 20 years of experience in academic and industrial R&D including 12 years at Roche, most recently serving as the Senior Vice President and Head of Neuroscience, Ophthalmology and Rare Diseases, as well as Small Molecule Research. In this capacity, he advanced over 20 NMEs to the clinic and various NMEs to registration studies. Currently Dr. Santarelli is the Chief Executive Officer and cofounder of Therachon AG, a global biotechnology company focused on developing treatments for rare, genetic diseases.

Search for content on Stalicla...